Copyright © 1995 by the European Society of Cardiology.
© 1995 The European Society of Cardiology
Extension of Native Aortic Valve Endocarditis: Surgical Considerations
* Departments of Cardiovascular Surgery and Cardiology
Clinics of the Catholic University of Louvain (UCL) Brussels and Mont-Godinne, Belgium
Correspondence to: Prof. J. C Schoevaerdts, Cliniques Universitaires Saint-Luc, Service de Chirurgie cardiovasculaire et thoracique, Avenue Hippocrate, 10, B-1200 Bruxelles, Belgium.
Among 101 consecutive patients operated on for native infective aortic valve endocarditis (53 males, 48 females, mean age 39 years), 69 presented various forms of infectious extension to the surrounding areas. Twenty-six lesions were noted in the aortic roots: 18 annular abscesses, one abscess of the Valsalva sinus and seven aortic wall destructions. Among the subaortic valve pathology, 27 cases of septal lesions were noted and in one case the mitral fibrous trigone was involved. The mitral apparatus was infected in 26 cases, the tricuspid valvule in one case. Both tricuspid and mitral valvular replacements had to be performed in five cases. Among the 16 postoperative atrioventricular blocks, 14 needed a pacemaker. The most frequent causative microorganisms were Staphylococcus aureus and Streptococcus. Surgical management of the lesions consisted of extensive debridement followed by either simple repair of defects or complex reconstructions involving pericardial or synthetic patches or other more complex operations. Early and late mortality rates were 8.5% and 16%; early and late reoperation rates were 6% and 9.5%, respectively. The mean follow-up time was 148 months (12–265 months) with a survival of 74% (SE: ± 0.08) at 10 years. We conclude that, although surgical correction of infective endocarditis may need a complex approach, it provides good results with an acceptable surgical risk.
Key Words: Infective endocarditis • surgery of endocarditis • aortic root abscess • pericardial patch
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Frankenstein, C. Zugck, D. Schellberg, M. Nelles, H. Froehlich, H. Katus, and A. Remppis Prevalence and prognostic significance of adrenergic escape during chronic {beta}-blocker therapy in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 178 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur J Heart Fail, January 1, 2009; 11(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Perrier, B.-G. Kerfant, N. Lalevee, P. Bideaux, M. F. Rossier, S. Richard, A. M. Gomez, and J.-P. Benitah Mineralocorticoid Receptor Antagonism Prevents the Electrical Remodeling That Precedes Cellular Hypertrophy After Myocardial Infarction Circulation, August 17, 2004; 110(7): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]
|
|
|
|
|
|
U. P. Jorde, T. Vittorio, S. D. Katz, P. C. Colombo, F. Latif, and T. H. Le Jemtel Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure Circulation, August 27, 2002; 106(9): 1055 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Roig, F Perez-Villa, M Morales, W Jimenez, J Orus, M Heras, and G Sanz Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure Eur. Heart J., January 1, 2000; 21(1): 53 - 57. [Abstract] [PDF]
|
|